You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Launched last month as part of the EU's coronavirus action plan, the portal will collect and distribute SARS-CoV-2 sequencing and patient phenotype data.
Mount Sinai bioinformaticians have quickly pivoted from Lyme disease research to building a reference tool for researchers pursuing COVID therapies.
Genomics England has slashed storage costs by migrating to a new file system, while NIH's All of Us research program is seeking savings from a cloud environment.
Policies regarding data sharing and re-use also influenced people's willingness to contribute their genomic data to resources run by various types of organizations.
The company hopes to help consumer genomics firms and healthcare companies reduce the IT burdens associated with launching a new test.
The Medical Genome Reference Bank, which currently holds data for more than 2,500 healthy elderly Australians, could help scientists understand the genetics of healthy aging.
The Scottish bioinformatics firm will crunch multi-omic datasets to assist Charles River Laboratories in "data-driven" drug discovery.
The Michael J. Fox Foundation-led project aims to lead researchers to new insights about biomarkers indicating Parkinson's disease progression.
While the Oxford, UK-based company has focused on drug development partnerships to date, it is also keen to see uptake of genetic disease risk screening by the NHS.
The companies will combine clinical genetic testing services with data management technology to support precision medicine for rare diseases.
Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.
Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.
New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.
In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.